Results 161 to 170 of about 3,811,568 (245)

Undifferentiated Castration-Resistant Prostate Cancer Successfully Treated With Carboplatin and Paclitaxel. [PDF]

Case Rep Urol
Sano M, Shimbo M, Ohgita S, Kanomata N, Hattori K, Endo F.   +5 more
europepmc   +1 more source

Correction: Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer. [PDF]

Prostate Cancer Prostatic Dis
Csizmarik A, Nagy N, Keresztes D, Váradi M, Bracht T, Sitek B, Witzke K, Puhr M, Tornyi I, Lázár J, Takács L, Kramer G, Sevcenco S, Maj-Hes A, Hadaschik B, Nyirády P, Szarvas T.   +16 more
europepmc   +1 more source

Incorporating Metastatic Disease Burden into Prognostic Assessment in Metastatic Castration-Resistant Prostate Cancer: The MIRA Score. [PDF]

Cancers (Basel)
Uccello M, Vlachostergios PJ, Ghose A, Boussios S.   +3 more
europepmc   +1 more source

Darolutamide With Concomitant Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer.

JAMA Netw Open
Luz MA, Briganti A, Murphy DG, Pieczonka CM, Suzuki H, Yu EY, Artignan X, Gotto GT, Hamilton JP, Malone RJ, Adorjan P, Ghadessi M, Verholen F, Armstrong AJ.   +13 more
europepmc   +1 more source

Expression of Concern for EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates antitumor activity in metastatic castration-resistant prostate cancer. [PDF]

J Clin Invest
Fang B, Li X, Lu Y, Ma W, Gan H, Zhang T, Liu Q, Wang B, Wang Z, Zhu Y, Zhu H, Xiao S, Bian X, Wei G, Ye D, Zhu Y.   +15 more
europepmc   +1 more source

Bone-Modifying Agents in Metastatic Castration-Resistant Prostate Cancer.

JAMA Netw Open
Ozay ZI, Jo Y, Gebrael G, Ostrowski M, Mathew Thomas V, Li H, Graf RP, Roy S, Maughan BL, Guha A, Riaz IB, Antonarakis ES, McKay RR, Agarwal N, Swami U.   +14 more
europepmc   +1 more source

PSMA-RECAP: [¹⁷⁷Lu]Lu-PSMA-617 retreatment in metastatic castration-resistant prostate cancer. [PDF]

Front Oncol
Belge Bilgin G, Bilgin C, Packard AT, Burkett BJ, Oztekin ES, Thorpe MP, Childs DS, Muniz M, Stoff R, Nikanpour Y, Orme JJ, Kwon ED, Johnson GB, Sartor O, Johnson DR, Kendi AT.   +15 more
europepmc   +1 more source

Treatment Patterns and Attrition in Metastatic Castration-Resistant Prostate Cancer.

JAMA Netw Open
Hooper G, Jo Y, Nandakumar V, Gebrael G, Ozay ZI, Ostrowski M, Hardy T, Lin E, Campbell P, Murdock EG, Upadhyay L, Goel K, Thomas VM, Li H, Sokolova AO, Swami U, Agarwal N.   +16 more
europepmc   +1 more source

Docosahexaenoic Acid Enhances the Cytotoxic Effects of Enzalutamide and the PARP Inhibitor in Castration-Resistant Prostate Cancer Cell Lines. [PDF]

Int J Mol Sci
da Silva ADT, Ferreira LDP, Ribeiro DL, Tamarindo GH, Góes RM.   +4 more
europepmc   +1 more source

Satisfaction with treatment decision-making and long-term experiences of life-prolonging treatments for metastatic castration-resistant prostate cancer. [PDF]

BMC Palliat Care
Routier Cañigueral P, Wennman-Larsen A, Doveson S, Rönningås U, Holm M.   +4 more
europepmc   +1 more source